文献速递肾小球疾病

糖皮质激素调节的分子特征及IgA肾病疗效预测

Glucocorticoid-Modulated Molecular Signatures and Prediction of Treatment Efficacy in IgA Nephropathy.
PubMed 文献 · J Am Soc Nephrol · 2026-07-31

发现302个糖皮质激素调节蛋白,但补体激活和内皮损伤通路未被调节;瘦素和C1QTNF5可改善糖皮质激素疗效预测,联合模型5年AUC为0.85。

要点

  • 糖皮质激素调节302个蛋白,富集于细胞骨架稳定和免疫代谢通路。
  • 补体激活和内皮损伤通路不受糖皮质激素调节,提示联合治疗靶点。
  • 瘦素和C1QTNF5联合临床变量可提升糖皮质激素疗效预测。

核心结论

  • 基于随机对照试验的蛋白质组学分析识别了糖皮质激素调节的蛋白和通路,并发现可分层预测糖皮质激素治疗获益的蛋白生物标志物。

主要发现

  • 在检测到的1500余种蛋白中,302种受糖皮质激素调节,富集于细胞骨架稳定和免疫代谢通路。
  • 与长期eGFR下降相关的补体激活和内皮损伤通路未受糖皮质激素调节。
  • 瘦素和C1QTNF5经ELISA验证,包含这两蛋白的预测模型在预测糖皮质激素疗效方面显著优于传统临床模型,5年AUC为0.85(95%CI 0.72–0.88)对比0.80(95%CI 0.78–0.91)。

临床怎么用

  • 瘦素和C1QTNF5或可用于早期识别更可能从糖皮质激素治疗中获益的IgA肾病患者,辅助治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Serum proteomics on the basis of the Therapeutic Evaluation of Steroids in IgA Nephropathy Global trial revealed glucocorticoid-modulated proteins in IgA nephropathy. Complement and endothelial injury modules persisted despite glucocorticoid treatment, suggesting complementary therapeutic targets. Leptin and C1QTNF5 improved prediction of glucocorticoid efficacy and may guide therapeutic decisions. BACKGROUND: Glucocorticoids remain an important anti-inflammatory therapy for IgA nephropathy but are associated with substantial treatment-related adverse effects, highlighting the urgent need for early prediction of treatment efficacy. We hypothesized that randomized controlled trial-based serum proteomic profiling could delineate glucocorticoid-modulated proteins and more accurately stratify patients likely to benefit from glucocorticoid therapy. METHODS: We performed proteomic analyses of samples from the Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) trial, in which patients with IgA nephropathy were randomized to receive methylprednisolone or placebo. Four hundred seventy-nine longitudinal serum samples from 241 Chinese participants collected at baseline and at 6 and 12 months were analyzed. Linear mixed-effect models were used to identify glucocorticoid-modulated proteins and pathways in the methylprednisolone group relative to placebo. Cox proportional hazards and penalized ridge regression models were used to prioritize proteins and develop a prediction model for therapeutic efficacy. The candidate proteins were further validated by ELISA. RESULTS: Among more than 1500 detected proteins, 302 were glucocorticoid modulated and enriched in pathways of cytoskeletal stabilization and immunometabolism. Notably, pathways associated with long-term eGFR decline, such as complement activation and endothelial injury, were not modulated by glucocorticoids. Among the glucocorticoid-modulated proteins, Cox proportional hazards and penalized ridge regression models identified those whose baseline levels improved prediction of treatment efficacy compared with clinical variables alone. ELISA was used to validate selected candidate proteins leptin and C1QTNF5. The prediction model incorporating these two proteins significantly outperformed the traditional clinical model in predicting glucocorticoid efficacy (5-year area under the curve, 0.85 [95% confidence interval, 0.72 to 0.88] versus 0.80 [95% confidence interval, 0.78 to 0.91]). CONCLUSIONS: Data from this randomized trial-based proteomic study helped delineate glucocorticoid-modulated proteins and pathways and identified robust protein biomarkers that enabled stratification of patients likely to benefit from glucocorticoid therapy.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Wang L, He Y, Tian W, et al. Glucocorticoid-Modulated Molecular Signatures and Prediction of Treatment Efficacy in IgA Nephropathy. J Am Soc Nephrol. 2026. PMID: 42536435. doi:10.1681/ASN.0000001208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。